en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background:</span></span></span></span></span></span> <span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">This study investigates the impact of novel anticoagulants on bleeding risk and thrombosis in critically ill patients, with a special focus on those who are exposed to radiation therapy. We compare the safety and efficacy of rivaroxaban and apixaban to traditional anticoagulants to assess their role in radiation-induced coagulopathies. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Materials and Methods: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">A total of 400 critically ill patients requiring anticoagulation were included. Patients were divided into two groups: the experimental group received novel anticoagulants, and the control group received traditional anticoagulants (heparin or low molecular weight heparin). Radiotherapy was administered based on standard protocols to patients with various cancers, including breast, lung, gastrointestinal, and head and neck cancers. Various bleeding and coagulation parameters, including activated partial thromboplastin time (aPTT) and prothrombin time (PT), were measured to assess thrombotic and bleeding risks. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Results: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">The experimental group showed a significant reduction in the incidence of thromboembolic events compared to the control group. The novel anticoagulants demonstrated significantly fewer bleeding complications and a more favorable safety profile. Radiological imaging used to assess pulmonary embolism or deep vein thrombosis also suggested lower follow-up requirements in the experimental group, hinting at the efficiency of novel anticoagulation strategies in reducing the need for radiation-based diagnostics. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Conclusion: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">The use of novel anticoagulants in critically ill patients exposed to radiotherapy appears to effectively balance the anticoagulation benefit with a reduced bleeding risk, offering a potential alternative to traditional therapies. Their ability to manage radiation-induced coagulopathies and reduce complications could enhance the overall care and outcomes of radiation-exposed patients.</span></span></span></span></span></span></span></span></span></span></div> Novel anticoagulants, radiotherapy, bleeding risk, Rivaroxaban, Apixaban, coagulopathies. 237 244 http://ijrr.com/browse.php?a_code=A-10-1-1481&slc_lang=en&sid=1 Z. Lin 7900319475328460032982 7900319475328460032982 No Department of Hepatobiliary Surgery, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China R. Ma 7900319475328460032983 7900319475328460032983 No Department of Hepatobiliary Surgery, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China Z. Wang 7900319475328460032984 7900319475328460032984 No Department of Hepatobiliary Surgery, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China X. Fu 7900319475328460032985 7900319475328460032985 No Deputy Director, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China H. Jiao 7900319475328460032986 7900319475328460032986 No Department of Hepatobiliary Surgery, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China D. Wang 7900319475328460032987 7900319475328460032987 No Outpatient Department, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China J. Yu 7900319475328460032988 7900319475328460032988 No Department of Hepatobiliary Surgery, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China J. Wang 7900319475328460032989 7900319475328460032989 No Department of Hepatobiliary Surgery, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China Y. An 7900319475328460032990 7900319475328460032990 No Department of Hepatobiliary Surgery, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China X. Yu 18999223109@163.com 7900319475328460032991 7900319475328460032991 Yes Department of Hepatobiliary Surgery, People's Armed Police Force Xinjiang Corps General Hospital, Urumqi, China